Prostate cancer is cancer that occurs in the prostate. Prostate cancer is the most frequently diagnosed male cancer and the fifth leading cancer-related mortality rate in men around the world. In 2020, there were 1,414,249 newly diagnosed cases and 375,000 fatalities worldwide due to this illness. The majority of prostate tumors grow slowly, are low-grade, have a modest risk, and are not particularly aggressive.
Age - Men under the age of 40 are less likely to develop prostate cancer than older men, although the risk increases significantly after age 50. Men older than 65 are infected by prostate cancer in about 6 out of 10 cases
Race/ethnicity - A man's risk of having prostate cancer is more than doubled if his father or sibling has the condition
Gene changes - Inherited mutations in the BRCA1 or BRCA2 genes linked to an elevated risk of breast and ovarian cancer can also raise the risk of prostate cancer in men (especially mutations in BRCA2)
Prostate cancer risk is higher in men who have Lynch syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC), a disorder caused by inherited gene alterations
Screening for prostate cancer - Prostate screening tests include:
1. Prostatectomy – includes the removal of affected tissues and lymph nodes of the prostate gland. This can be done by 2 techniques:
2. Radiation therapy includes -
3. Freezing or heating prostate tissue -
4. Chemotherapy
5. Immunotherapy
6. Targeted drug therapy
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
An individual state lost $4.02 billion due to untreated mental illness.
2.
Antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer
3.
Black Canadians Face Multiple Barriers to Blood Donation
4.
Study: Discovery of cellular identity may influence cancer treatment
5.
Early-life exposure to air and light pollution linked to increased risk of pediatric thyroid cancer
1.
Drug Safety Through Oncology Survivorship Medication Monitoring Frameworks
2.
Digital Oncology Navigation Systems for Coordinated Multidisciplinary Cancer Care
3.
Simulation for Hematology Emergencies: Enhancing Clinical Preparedness and Patient Outcomes
4.
Colon Cancer Staging: What You Need to Know
5.
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
How Multidisciplinary Teams Support Modern Cancer Care
2.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
3.
Navigating the Complexities of Ph Negative ALL - Part II
4.
Navigating the Complexities of Ph Negative ALL - Part VIII
5.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation